Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are QDEL, EOLS, AMLX, ADMA, GLPG, and represent 67.05% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: AMLX (+$26M), ALIM (+$12M), GMDA (+$6.7M), EOLS (+$6.1M), GLPG, AVIR, QDEL, IOBT, GOSS, ASRT.
- Started 5 new stock positions in GOSS, ALIM, IOBT, VNDA, ASRT.
- Reduced shares in these 6 stocks: THRD (-$13M), URGN, CSTL, MXCT, SCYX, LIFE.
- Sold out of its positions in CSTL, THRD, URGN.
- Stonepine Capital Management was a net buyer of stock by $56M.
- Stonepine Capital Management has $301M in assets under management (AUM), dropping by 8.59%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 23 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Quidel Corp (QDEL) | 16.0 | $48M | +6% | 659k | 73.04 |
|
| Evolus (EOLS) | 15.7 | $47M | +14% | 5.2M | 9.14 |
|
| Amylyx Pharmaceuticals (AMLX) | 15.3 | $46M | +124% | 2.5M | 18.31 |
|
| Adma Biologics (ADMA) | 10.8 | $33M | +3% | 9.1M | 3.58 |
|
| Galapagos Nv- Spons Adr (GLPG) | 9.2 | $28M | +17% | 803k | 34.55 |
|
| Alimera Sciences Com New (ALIM) | 4.1 | $12M | NEW | 4.0M | 3.10 |
|
| Maxcyte (MXCT) | 3.9 | $12M | -5% | 3.8M | 3.12 |
|
| Xeris Pharmaceuticals (XERS) | 3.7 | $11M | +7% | 5.9M | 1.86 |
|
| Gamida Cell SHS (GMDA) | 2.7 | $8.2M | +431% | 8.0M | 1.03 |
|
| Atyr Pharma Com New (LIFE) | 2.4 | $7.3M | 4.6M | 1.58 |
|
|
| Scynexis Com New (SCYX) | 2.2 | $6.5M | -3% | 2.9M | 2.28 |
|
| Xoma Corp Com New (XOMA) | 2.0 | $6.2M | +24% | 437k | 14.09 |
|
| X4 Pharmaceuticals (XFOR) | 1.9 | $5.7M | +14% | 5.3M | 1.09 |
|
| Atea Pharmaceuticals (AVIR) | 1.7 | $5.2M | +128% | 1.7M | 3.00 |
|
| Rezolute Com New (RZLT) | 1.3 | $4.1M | 3.1M | 1.32 |
|
|
| Tela Bio (TELA) | 1.3 | $3.9M | 492k | 8.00 |
|
|
| Exagen (XGN) | 1.0 | $2.9M | +14% | 1.2M | 2.42 |
|
| Io Biotech (IOBT) | 0.9 | $2.8M | NEW | 2.0M | 1.41 |
|
| Gossamer Bio (GOSS) | 0.9 | $2.8M | NEW | 3.3M | 0.83 |
|
| Delcath Systems Com New (DCTH) | 0.9 | $2.8M | +81% | 686k | 4.05 |
|
| Assertio Holdings Com New (ASRT) | 0.8 | $2.4M | NEW | 951k | 2.56 |
|
| Vanda Pharmaceuticals (VNDA) | 0.7 | $2.1M | NEW | 478k | 4.32 |
|
| Aytu Biopharma (AYTU) | 0.4 | $1.3M | 472k | 2.70 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023
- Stonepine Capital Management 2023 Q1 filed May 12, 2023
- Stonepine Capital Management 2022 Q4 filed Feb. 14, 2023
- Stonepine Capital Management 2022 Q3 filed Nov. 10, 2022
- Stonepine Capital Management 2022 Q2 filed Aug. 12, 2022
- Stonepine Capital Management 2022 Q1 filed May 16, 2022
- Stonepine Capital Management 2021 Q4 filed Feb. 14, 2022
- Stonepine Capital Management 2021 Q3 filed Nov. 12, 2021
- Stonepine Capital Management 2021 Q2 restated filed Aug. 16, 2021
- Stonepine Capital Management 2021 Q2 filed Aug. 13, 2021
- Stonepine Capital Management 2021 Q1 filed May 14, 2021
- Stonepine Capital Management 2020 Q4 filed Feb. 12, 2021
- Stonepine Capital Management 2020 Q3 filed Nov. 13, 2020
- Stonepine Capital Management 2020 Q2 filed Aug. 13, 2020